Join
Live feed
·
PRReleasevia Quantisnow
Alector Inc. logo

Alector to Discontinue Phase 2 PROGRESS-AD Trial of Nivisnebart (AL101/GSK4527226) in Early Alzheimer's Disease Following Interim Futility Analysis

ByQuantisnow·Wall Street's wire, on your screen.
ALEC· Alector Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track ALEC (Alector Inc.) and more on Quantisnow.